+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rheumatoid Arthritis Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 150 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5662089

Global Rheumatoid Arthritis Therapeutics Market to Reach $66.7 Billion by 2030

The global market for Rheumatoid Arthritis Therapeutics estimated at US$48.3 Billion in the year 2022, is projected to reach a revised size of US$66.7 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2022-2030. Pharmaceuticals, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$28 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biopharmaceuticals segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $13.2 Billion, While China is Forecast to Grow at 6.9% CAGR

The Rheumatoid Arthritis Therapeutics market in the U.S. is estimated at US$13.2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$13.8 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 3.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Select Competitors (Total 23 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • UCB SA

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Rheumatoid Arthritis Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Biopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Prescription by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Over-the-Counter (OTC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 16: World Rheumatoid Arthritis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 18: USA Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: USA 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 20: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: USA 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: Canada 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Canada 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
JAPAN
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: Japan 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 32: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Japan 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
CHINA
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: China Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: China 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 38: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: China Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: China 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
EUROPE
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 41: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
FRANCE
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 50: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: France Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: France 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 53: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: France Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: France 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
GERMANY
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 56: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: Germany Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Germany 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 59: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: Germany 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
ITALY
  • Table 62: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Italy Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: Italy 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 65: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: Italy 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 68: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: UK Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: UK 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 71: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: UK Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: UK 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
SPAIN
  • Table 74: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: Spain Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: Spain 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 77: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: Spain Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: Spain 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
RUSSIA
  • Table 80: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: Russia Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: Russia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 83: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: Russia Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: Russia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 86: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Rest of Europe Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 93: Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 97: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
AUSTRALIA
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • UCB SA

Table Information